Nancy Miller-rich - Net Worth and Insider Trading

Nancy Miller-rich Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Nancy Miller-rich owns 4 companies in total, including Kadmon Holdings Inc (KDMN) , Aldeyra Therapeutics Inc (ALDX) , and Intercept Pharmaceuticals Inc (ICPT) among others .

Click here to see the complete history of Nancy Miller-rich’s form 4 insider trades.

Insider Ownership Summary of Nancy Miller-rich

Ticker	Comapny	Transaction Date	Type of Owner
KDMN	Kadmon Holdings Inc	2020-08-13	director
ALDX	Aldeyra Therapeutics Inc	2020-01-13	director
ICPT	Intercept Pharmaceuticals Inc	2020-05-28	director
FDMT	4D Molecular Therapeutics Inc	2020-12-10	director

Nancy Miller-rich Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Nancy Miller-rich Ownership Network

Ownership Network List of Nancy Miller-rich

No Data

Ownership Network Relation of Nancy Miller-rich

Nancy Miller-rich Owned Company Details

What does Kadmon Holdings Inc do?

Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.

Who are the key executives at Kadmon Holdings Inc?

Nancy Miller-rich is the director of Kadmon Holdings Inc. Other key executives at Kadmon Holdings Inc include director & President & CEO Harlan Waksal , Executive Vice President & CMO John L Ryan , and EVP & Chief Financial Officer Steven Meehan .

Kadmon Holdings Inc (KDMN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kadmon Holdings Inc (KDMN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kadmon Holdings Inc (KDMN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kadmon Holdings Inc (KDMN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kadmon Holdings Inc Insider Transactions

No Available Data

What does Aldeyra Therapeutics Inc do?

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Who are the key executives at Aldeyra Therapeutics Inc?

Nancy Miller-rich is the director of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include See Remarks Bruce Greenberg , Chief Development Officer Stephen Machatha , and 10 percent owner Joseph Edelman .

Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary

Over the past 18 months, Nancy Miller-rich made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net purchase of 1,305,206 shares made by Perceptive Life Sciences Master Fund Ltd , a net purchase of 17,700 shares made by Todd C Brady , and a net purchase of 4,323 shares made by Martin Joseph Joyce .

In summary, during the past 3 months, insiders sold 0 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 1,327,229 shares were bought by its insiders, resulting in a net purchase of 1,327,229 shares.

Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aldeyra Therapeutics Inc Insider Transactions

No Available Data

What does Intercept Pharmaceuticals Inc do?

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Who are the key executives at Intercept Pharmaceuticals Inc?

Nancy Miller-rich is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

What does 4D Molecular Therapeutics Inc do?

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Who are the key executives at 4D Molecular Therapeutics Inc?

Nancy Miller-rich is the director of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include director & Chief Executive Officer David Kirn , Chief Legal and HR Officer Scott Bizily , and Chief Medical Officer Robert Young Kim .

4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary

Over the past 18 months, Nancy Miller-rich made no insider transaction in 4D Molecular Therapeutics Inc (FDMT). Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 140,847 shares made by David Kirn , a net sale of 11,998 shares made by Scott Bizily , and a net purchase of 850,000 shares made by Viking Global Investors Lp .

In summary, during the past 3 months, insiders sold 8,750 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 850,000 shares, with a net purchase of 841,250 shares. During the past 18 months, 157,845 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 850,000 shares were bought by its insiders, resulting in a net purchase of 692,155 shares.

4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

4D Molecular Therapeutics Inc Insider Transactions

No Available Data

Nancy Miller-rich Mailing Address

Above is the net worth, insider trading, and ownership report for Nancy Miller-rich. You might contact Nancy Miller-rich via mailing address: C/o Intercept Pharmaceuticals, Inc., 10 Hudson Yards, 37th Fl, New York Ny 10001.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF ADV Part 2A ADV Part 2B ADV Part 3 Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.